secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIO-RAD LABORATORIES, INC. (BIO)
CIK:        0000012208
Form:       8-K
Filed at:   2021-10-28T23:59:59+00:00
Accession:  0000012208-21-000045
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bio-Rad Q3 revenue $747M (+15.4% YoY); non-GAAP EPS $3.71; raises FY21 guidance
-------------------------------------------------------------------------------

- Life Science segment revenue $373.5M (+15.3% YoY); Clinical Diagnostics $372.2M (+15.5% YoY).
- GAAP net income $3.93B ($129.96 diluted EPS) driven by $4.87B unrealized gain on Sartorius equity.
- Non-GAAP net income $112.2M ($3.71 diluted EPS) vs $90.3M ($3.00) a year ago.
- Full-year 2021 guidance: non-GAAP currency-neutral revenue growth 12-13%; operating margin ~19.5%.
- Gross margin improved to 58.6% from 56.7%; operating margin 21.0% vs 16.9%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/12208/000001220821000045/0000012208-21-000045-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/12208/000001220821000045/bio-20211028.htm
  HTML page:      https://secwatch.observer/filing/0000012208-21-000045

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer